Alnylam Pharmaceuticals Reports Financial Condition
Ticker: ALNY · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1178670
Sentiment: neutral
Topics: financial-condition, operations-report
Related Tickers: ALNY
TL;DR
Alnylam dropped an 8-K on Jan 12th about their financials. Check it for deets.
AI Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on Results of Operations and Financial Condition as of January 12, 2025. The filing does not contain specific financial figures or operational details in the provided text, but indicates a report on the company's financial status.
Why It Matters
This filing provides an update on Alnylam Pharmaceuticals' financial performance and condition, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial condition, and the provided text does not contain any negative or unusual information.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer
- January 13, 2025 (date) — Filing Date
- January 12, 2025 (date) — Date of Earliest Event Reported
- 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Alnylam Pharmaceuticals, Inc.
On what date is the earliest event reported in this filing?
The earliest event reported in this filing is dated January 12, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on January 13, 2025.
What is Alnylam Pharmaceuticals, Inc.'s principal executive office address?
Alnylam Pharmaceuticals, Inc.'s principal executive office is located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142.
What is the SEC file number for Alnylam Pharmaceuticals, Inc.?
The SEC file number for Alnylam Pharmaceuticals, Inc. is 001-36407.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-13 07:31:19
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Sto
- $451 million — l net product revenues of approximately $451 million and $1,646 million, respectively, for O
- $1,646 m — enues of approximately $451 million and $1,646 million, respectively, for ONPATTRO (pati
Filing Documents
- alny-20250112.htm (8-K) — 27KB
- alny2025q1exhibit991.htm (EX-99) — 41KB
- logoforera.jpg (GRAPHIC) — 4KB
- 0001178670-25-000008.txt ( ) — 208KB
- alny-20250112.xsd (EX-101.SCH) — 2KB
- alny-20250112_lab.xml (EX-101.LAB) — 22KB
- alny-20250112_pre.xml (EX-101.PRE) — 13KB
- alny-20250112_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 12, 2025, Alnylam Pharmaceuticals, Inc. (the "Company") announced its preliminary fourth quarter and full year 2024 global net product revenues of approximately $451 million and $1,646 million, respectively, for ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran), and provided the Company's 2025 product and pipeline goals. The Company also announced full year 2025 combined net product revenue guidance and 2025 non-GAAP operating income guidance. The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2025. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Pres s Release dated January 12, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer